Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

Open to people ages 16 years and up

Incidence Phase

• CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
• HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.
• Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:
  • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
  • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
  • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

• Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
• Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).

Incidence Phase

• Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
• Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

• Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
• Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.